Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01947140 · ClinicalTrials.gov registry record · Phase 1
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
A Phase 1 study of Multiple Myeloma and Lymphoma, sponsored by Jennifer Amengual.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 3
- Study locations
NCT01947140 is a Phase 1 study of Multiple Myeloma and Lymphoma that has completed, run by Jennifer Amengual. The registered enrollment target is 57 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01947140, a Phase 1 study of Multiple Myeloma and Lymphoma, has completed, sponsored by Jennifer Amengual.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest. If the combination is determined to be safe, the study will continue accrual patients with peripheral T-Cell lymphoma (PTCL).
Conditions Studied
Interventions
- DRUG Pralatrexate
- DRUG Romidepsin
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New York
- Columbia University Irving Medical Center - New York
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-09-09 |
| Est. Completion | 2022-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01947140
The ClinicalTrials.gov registry entry for NCT01947140 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is Jennifer Amengual, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Pralatrexate is the first listed.
NCT01947140 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01947140 about?
NCT01947140 is a clinical study titled "Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies". This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest. If the combination is determined to be safe, the study will continue accrual patients with periph...
What is the current status of trial NCT01947140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2013-09-09. Estimated completion is 2022-09-01.
What conditions does trial NCT01947140 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Lymphoid Malignancies.
What interventions are being tested in trial NCT01947140?
The interventions under investigation include: Pralatrexate (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT01947140?
This trial is sponsored by Jennifer Amengual, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01947140 being conducted?
This trial has 3 study locations across Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.